Niket K. Shah

Niket K. Shah

Internal Medicine

801 S. Washington St.
Hospitalists-3rd Floor
Naperville, IL 60540

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

ConLymphNet: A Generalizable Region-Constrained Deep Learning Architecture for Precise Abdominal Lymph Node Segmentation Across Cancer Types.

ConLymphNet: A Generalizable Region-Constrained Deep Learning Architecture for Precise Abdominal Lymph Node Segmentation Across Cancer Types.

Journal: JCO clinical cancer informatics

Published: July 15, 2026

Venous Thromboembolism Risk in Transgender Women on Feminizing Hormone Therapy: A Narrative Review of Formulation-Specific Risks, Management Strategies, and Evidence Gaps.

Venous Thromboembolism Risk in Transgender Women on Feminizing Hormone Therapy: A Narrative Review of Formulation-Specific Risks, Management Strategies, and Evidence Gaps.

Journal: Cureus

Published: June 18, 2026

Management of Acute Myeloid Leukemia in a Dialysis-Dependent Patient: A Case Report, Literature Review, and Therapeutic Considerations.

Management of Acute Myeloid Leukemia in a Dialysis-Dependent Patient: A Case Report, Literature Review, and Therapeutic Considerations.

Journal: Cureus

Published: June 12, 2026

Platypnea-Orthodeoxia Syndrome Presenting With Secondary Erythrocytosis.

Platypnea-Orthodeoxia Syndrome Presenting With Secondary Erythrocytosis.

Journal: Cureus

Published: May 17, 2026

BPI26-029: Analysis of Racial Demographic Reporting in Clinical Studies Supporting the NCCN Esophageal & Esophagogastric Junction Cancer Guidelines.

BPI26-029: Analysis of Racial Demographic Reporting in Clinical Studies Supporting the NCCN Esophageal & Esophagogastric Junction Cancer Guidelines.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 30, 2026

HSR26-234: Real-World and Clinical Outcomes of Immunotherapy-Based Regimens Versus Tyrosine Kinase Inhibitor Monotherapy in First-Line Metastatic Papillary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.

HSR26-234: Real-World and Clinical Outcomes of Immunotherapy-Based Regimens Versus Tyrosine Kinase Inhibitor Monotherapy in First-Line Metastatic Papillary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 29, 2026

CRE26-057: Rare Transformation of JAK2-Positive Primary Myelofibrosis to B-Cell Acute Lymphoblastic Leukemia: A Case Report and Molecular Analysis.

CRE26-057: Rare Transformation of JAK2-Positive Primary Myelofibrosis to B-Cell Acute Lymphoblastic Leukemia: A Case Report and Molecular Analysis.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 29, 2026

HSR26-207: Real-World Survival and Toxicity Outcomes of Tarlatamab in Relapsed or Refractory Small-Cell Lung Cancer: A Multicenter TriNetX Analysis Across Academic and Non-Academic Centers.

HSR26-207: Real-World Survival and Toxicity Outcomes of Tarlatamab in Relapsed or Refractory Small-Cell Lung Cancer: A Multicenter TriNetX Analysis Across Academic and Non-Academic Centers.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

CRE26-050: Expanding Therapeutic Boundaries: Durable Remission of EBV-Positive NK/T-Cell Lymphoma With Pembrolizumab in the Setting of Renal Dysfunction.

CRE26-050: Expanding Therapeutic Boundaries: Durable Remission of EBV-Positive NK/T-Cell Lymphoma With Pembrolizumab in the Setting of Renal Dysfunction.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

Hemorrhagic Ascites in Chronic Lymphocytic Leukemia With Immunoglobulin Heavy Chain Variable Region 3-21 (IGHV3-21) Usage: A Case Requiring Individualized Treatment.

Hemorrhagic Ascites in Chronic Lymphocytic Leukemia With Immunoglobulin Heavy Chain Variable Region 3-21 (IGHV3-21) Usage: A Case Requiring Individualized Treatment.

Journal: Cureus

Published: April 05, 2026

HSR26-207: Real-World Survival and Toxicity Outcomes of Tarlatamab in Relapsed or Refractory Small-Cell Lung Cancer: A Multicenter TriNetX Analysis Across Academic and Non-Academic Centers.

HSR26-207: Real-World Survival and Toxicity Outcomes of Tarlatamab in Relapsed or Refractory Small-Cell Lung Cancer: A Multicenter TriNetX Analysis Across Academic and Non-Academic Centers.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 31, 2026

CRE26-057: Rare Transformation of JAK2-Positive Primary Myelofibrosis to B-Cell Acute Lymphoblastic Leukemia: A Case Report and Molecular Analysis.

CRE26-057: Rare Transformation of JAK2-Positive Primary Myelofibrosis to B-Cell Acute Lymphoblastic Leukemia: A Case Report and Molecular Analysis.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 31, 2026

Showing 1-12 of 28

Last Updated: 09/26/2026